JP2019516768A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516768A5
JP2019516768A5 JP2018561725A JP2018561725A JP2019516768A5 JP 2019516768 A5 JP2019516768 A5 JP 2019516768A5 JP 2018561725 A JP2018561725 A JP 2018561725A JP 2018561725 A JP2018561725 A JP 2018561725A JP 2019516768 A5 JP2019516768 A5 JP 2019516768A5
Authority
JP
Japan
Prior art keywords
peptide
immune checkpoint
ctl
cancer
apc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018561725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000740 external-priority patent/WO2017203362A1/en
Publication of JP2019516768A publication Critical patent/JP2019516768A/ja
Publication of JP2019516768A5 publication Critical patent/JP2019516768A5/ja
Withdrawn legal-status Critical Current

Links

JP2018561725A 2016-05-25 2017-05-25 がんの治療のための免疫チェックポイント阻害剤及び細胞傷害性ｔ細胞 Withdrawn JP2019516768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341402P 2016-05-25 2016-05-25
US62/341,402 2016-05-25
PCT/IB2017/000740 WO2017203362A1 (en) 2016-05-25 2017-05-25 Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2019516768A JP2019516768A (ja) 2019-06-20
JP2019516768A5 true JP2019516768A5 (https=) 2020-07-02

Family

ID=60411124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561725A Withdrawn JP2019516768A (ja) 2016-05-25 2017-05-25 がんの治療のための免疫チェックポイント阻害剤及び細胞傷害性ｔ細胞

Country Status (9)

Country Link
EP (1) EP3463398A4 (https=)
JP (1) JP2019516768A (https=)
KR (1) KR20190028664A (https=)
CN (1) CN109496155A (https=)
AR (1) AR108624A1 (https=)
AU (1) AU2017271128A1 (https=)
CA (1) CA3023845A1 (https=)
SG (1) SG11201809541UA (https=)
WO (1) WO2017203362A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997903B (zh) * 2017-08-10 2024-03-29 古德T细胞有限公司 用于癌症治疗的t细胞的活化方法
WO2020227279A1 (en) * 2019-05-06 2020-11-12 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
CN110452870A (zh) * 2019-05-20 2019-11-15 河南省肿瘤医院 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品
MX2022000667A (es) * 2019-07-15 2022-07-21 Neogene Therapeutics B V Metodo para aislar genes tcr.
JP2022554217A (ja) * 2019-10-23 2022-12-28 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 養子免疫療法
EP4162037A1 (en) * 2020-06-03 2023-04-12 MV Biotherapeutics SA Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002258941A1 (en) * 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
CN103536915A (zh) * 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
WO2010065959A1 (en) * 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
CN104769104A (zh) * 2011-12-12 2015-07-08 细胞药物有限公司 扩大t细胞的方法
JP6368308B2 (ja) * 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
WO2015157636A1 (en) * 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
CN107002038B (zh) * 2014-09-17 2021-10-15 约翰·霍普金斯大学 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法
JP7523203B2 (ja) * 2014-10-31 2024-07-26 マサチューセッツ インスティテュート オブ テクノロジー 生体分子の免疫細胞への送達

Similar Documents

Publication Publication Date Title
JP2019516768A5 (https=)
Li et al. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma
ES2894257T3 (es) Epítopos restringidos por MHC-E, moléculas de unión y métodos y usos relacionados
JP7705911B2 (ja) Ｈｉｖワクチン並びにその作製方法及び使用方法
JP7693813B2 (ja) Ｈｉｖワクチン及び使用方法
US20250312428A1 (en) Heterologous Prime Boost Vaccine
WO2021247534A2 (en) Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
Liu et al. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect
JP2019520332A5 (https=)
Tenesaca et al. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
AR108624A1 (es) Combinaciones terapéuticas para el tratamiento del cáncer
Wang et al. Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus
Seah et al. Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response
JP2024514707A (ja) 免疫療法における使用のための組成物及び方法
TWI921443B (zh) Ｈｉｖ疫苗及使用方法
US20240424090A1 (en) Compositions and methods for use in immunotherapy
Lim et al. Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance
Neerincx et al. Antibody-mediated delivery of TAPBPR enables the redirection of virus-specific T cell responses to tumour cells
Dlamini et al. Current immunotherapeutic treatments in colon cancer
Hagel Systematic interrogation of tumor cell resistance to CAR T cell therapy in pancreatic cancer
Tenesaca-Cayambe et al. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
HK40095916A (zh) Hiv疫苗及其使用方法
Vandeven Merkel Cell Carcinoma: Immunogenicity and the characterization of CD4 T cell responses to the Merkel cell polyomavirus